Bacterial resistance to antibiotics threatens the ability to treat life-threatening bloodstream infections. Oligonucleotides (ONs) composed of nucleic acid mimics (NAMs) able to inhibit essential genes can become an alternative to traditional antibiotics, as long as they are safely transported in human serum upon intravenous administration and they are carried across the multilayered bacterial envelopes, impermeable to ONs. In this study, fusogenic liposomes were considered to transport the ONs and promote their internalization in clinically relevant bacteria. Locked nucleic acids and 2′-OMethyl RNA were evaluated as model NAMs and formulated into DOTAP–DOPE liposomes followed by post-PEGylation. Our data showed a complexation stability between the post-PEGylated liposomes and the ONs of over 82%, during 24 h in native human serum, as determined by fluorescence correlation spectroscopy. Quantification by a lipid-mixing assay showed that liposomes, with and without post-PEGylation, fused with all bacteria tested. Such fusion promoted the delivery of a fraction of the ONs into the bacterial cytosol, as observed by fluorescence in situ hybridization and bacterial fractionation. In short, we demonstrated for the first time that liposomes can safely transport ONs in human serum and intracellularly deliver them in both Gram-negative and -positive bacteria, which holds promise towards the treatment of bloodstream infections.
The emergence of bacterial resistance to traditional small-molecule antibiotics is fueling the search for innovative strategies to treat infections. Inhibiting the expression of essential bacterial genes using antisense oligonucleotides (ASOs), particularly composed of nucleic acid mimics (NAMs), has emerged as a promising strategy. However, their efficiency depends on their association with vectors that can translocate the bacterial envelope. Vitamin B12 is among the largest molecules known to be taken up by bacteria and has very recently started to gain interest as a trojan-horse vector. Gapmers and steric blockers were evaluated as ASOs against Escherichia coli (E. coli). Both ASOs were successfully conjugated to B12 by copper-free azide-alkyne click-chemistry. The biological effect of the two conjugates was evaluated together with their intracellular localization in E. coli. Although not only B12 but also both B12-ASO conjugates interacted strongly with E. coli, they were mostly colocalized with the outer membrane. Only 6–9% were detected in the cytosol, which showed to be insufficient for bacterial growth inhibition. These results suggest that the internalization of B12-ASO conjugates is strongly affected by the low uptake rate of the B12 in E. coli and that further studies are needed before considering this strategy against biofilms in vivo.
The rise in antimicrobial resistance and the consequent ineffectiveness of conventional antibiotics emphasise the need for novel therapeutic strategies. Antisense nucleic acid mimics (NAMs) are emerging as promising precision therapeutic agents, inhibiting specific genes through hybridisation with selected nucleic acid targets. However, delivering NAMs into bacteria remains a significant challenge. This study explores the use of poly(amidoamine) (PAMAM) amphiphilic dendrimers (ADs) as delivery vehicles for NAMs targeting the essential acpP gene in Escherichia coli. Two ADs bearing primary amine or tertiary amine terminals, 1a and 1b, were tested for their ability to permeabilise the bacterial envelope, facilitate NAM internalisation, and enhance NAM-based antibacterial activity. Physicochemical characterisation studies, flow cytometry measurements, fluorescence and electron microscopy imaging, bacterial viability assays, and an in vivo toxicity assessment using a greater wax moth (Galleria mellonella) model were conducted. Both ADs acted as permeabilisers of the bacterial envelope and assisted in NAM internalisation and antibacterial activity. The most effective formulation, 1b combined with the peptide nucleic acid (PNA)-based NAM, achieved an 8 log10 reduction in viable bacteria, with sustained activity up to 24 h against E. coli. In vivo, the most promising formulations showed no toxicity, with G. mellonella larvae maintaining overall health and no significant mortality detected for up to three days. These findings demonstrate that amphiphilic dendrimers can effectively deliver PNA-based NAMs, highlighting their potential as a novel strategy against antimicrobial-resistant pathogens.